Literature DB >> 2477082

Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization.

D Scandella1, M Mattingly, S de Graaf, C A Fulcher.   

Abstract

Human factor VIII(FVIII) inhibitors are pathologic, circulating antibodies that inactivate FVIII. We have examined the location of epitopes on the FVIII protein for inhibitors from hemophilia A and nonhemophilic individuals. The inhibitors were of type I or type II in the kinetics of their inactivation of FVIII. A cDNA clone of human FVIII was used to express defined FVIII protein fragments in Escherichia coli for immunoblotting with inhibitor plasma. An epitope for 18 heavy-chain inhibitors was localized to the aminoterminal 18.3 Kd of the A2 domain. Two of these inhibitors also recognized an epitope located between A1 and A2 domains. Similarly, an epitope for 23 light-chain inhibitors was localized to the C2 domain. Weaker epitopes for 13 of the same inhibitors within the C1 and C2 domains were also observed. Four of the 23 inhibitors in addition bound strongly to the A3 domain. Most inhibitors (22 of 23) were neutralized in vitro only by the FVIII fragments to which they bound on immunoblots; however, one inhibitor that was neutralized by a fragment containing the A1 domain did not bind to it on immunoblots. Conversely, 3 of 3 inhibitors that bound to the A3 domain and 5 of 15 that bound to the A2 domain were not neutralized by the corresponding fragments. The epitope specificity of an inhibitor did not depend on its source or type. Our results show that FVIII inhibitors bind to limited areas within the heavy and light chains of FVIII. Some inhibitor plasmas contain additional antibodies that may not be inhibitory.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2477082

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals.

Authors:  M Algiman; G Dietrich; U E Nydegger; D Boieldieu; Y Sultan; M D Kazatchkine
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

2.  Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies.

Authors:  J G Gilles; J M Saint-Remy
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

Review 3.  Highly conserved antigenic structure of the factor VIII C2 domain in some mammals.

Authors:  Jun-ichi Ori; Ichiro Tanaka; Yoko Kubota; Midori Shima; Tomoko Matsumoto; Koichi Yoshida; Yoshihiko Sakurai; Akira Yoshioka
Journal:  Int J Hematol       Date:  2005-11       Impact factor: 2.490

4.  Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A.

Authors:  Joerg Kahle; Aleksander Orlowski; Diana Stichel; John F Healey; Ernest T Parker; Marc Jacquemin; Manuela Krause; Andreas Tiede; Dirk Schwabe; Pete Lollar; Christoph Königs
Journal:  Blood       Date:  2017-05-15       Impact factor: 22.113

Review 5.  Production of recombinant coagulation factors: Are humans the best host cells?

Authors:  Kamilla Swiech; Virgínia Picanço-Castro; Dimas Tadeu Covas
Journal:  Bioengineered       Date:  2017-02-23       Impact factor: 3.269

6.  Characterization of anti-factor VIII antibody in a patient with acquired hemophilia A.

Authors:  Jisu Oh; Yeongmin Lim; Moon Ju Jang; Ji Young Huh; Midori Shima; Doyeun Oh
Journal:  Blood Res       Date:  2013-03-25

7.  Factor VIII inhibitors in hemophilia A: rationale and latest evidence.

Authors:  Char Witmer; Guy Young
Journal:  Ther Adv Hematol       Date:  2013-02

Review 8.  B-cell and T-cell epitopes in anti-factor VIII immune responses.

Authors:  Kathleen P Pratt; Arthur R Thompson
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

9.  Inhibition of human factor VIIIa by anti-A2 subunit antibodies.

Authors:  P Lollar; E T Parker; J E Curtis; S L Helgerson; L W Hoyer; M E Scott; D Scandella
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

10.  Relationship between the binding sites for von Willebrand factor, phospholipid, and human factor VIII C2 inhibitor alloantibodies within the factor VIII C2 domain.

Authors:  Keiji Nogami; Midori Shima; John C Giddings; Masahiro Takeyama; Ichiro Tanaka; Akira Yoshioka
Journal:  Int J Hematol       Date:  2007-05       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.